GlomCon's Clinical Trial Portal
A platform to help HOPE
find OPPORTUNITY
Featured Clinical Trials
Atypical Hemolytic Uremic Syndrome
Study Sponsor: Novartis Pharmaceuticals
Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy (APPELHUS).
IC-MPGN
Study Sponsor: Novartis Pharmaceuticals
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (APPARENT).
C3 Glomerulopathy
Study Sponsor: Novartis Pharmaceuticals
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G).
IgA Nephropathy
Study Sponsor: Novartis Pharmaceuticals
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN).
GlomCon's Corporate Supporters
We gratefully acknowledge the support and partnership of corporations dedicated to improving the lives of patients with glomerular diseases.
​
The support from our corporate members and our strategic partners allows us to come up with bold ideas and helps us pursue our mission.
Contact Us
Questions? Concerns? Reach out to GlomCon's Clinical Trials team at support@glomcon.org